Sanofi Genzyme logo
IMPORTANT SAFETY INFORMATION: Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients... View more

Treatment
Options

There are two treatment approaches to help manage some of the signs and
symptoms of Gaucher disease type 1⁠— enzyme replacement or substrate
reduction, that both achieve the goal of reducing excessive GL-1.

Treatment options for Gaucher disease type 1

If you have been diagnosed with Gaucher disease type 1, treatment approaches are available to help manage certain signs and symptoms of the disease. The goal of these treatments is to reduce or prevent the buildup of GL-1. Treatment outcomes may vary among patients.

2 treatment approaches for Gaucher disease type 1:

Enzyme replacement therapy (ERT) by intravenous infusions

Enzyme replacement
therapy (ERT)

  • Intravenous (IV) infusions usually given every 2 weeks at an infusion center, a doctor’s office, or at home as medically appropriate (infusion takes approximately 1-2 hours)
  • Adds a modified version of the enzyme to help your body break down GL-1
Substrate reduction therapy (SRT)

Substrate reduction
therapy (SRT)

  • Oral medicine taken daily
  • Reduces the amount of GL-1 that is produced

Cerezyme is the ONLY ERT that has been prescribed for over 20 years. Talk to your doctor about your treatment options

Signs and symptoms

Signs and symptoms

Learn about the symptoms of Gaucher disease

See details
Personalized support and resources

Find support

Information, services, and resources to meet your needs

Get help

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  • anemia (low red blood cell count)
  • thrombocytopenia (low blood platelet count)
  • bone disease
  • hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).